Kanada - Ingliż - Health Canada

ranbaxy pharmaceuticals canada inc. - pravastatin sodium - tablet - 40mg - pravastatin sodium 40mg - hmg-coa reductase inhibitors

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

ucb pharma sa - lacosamide - epilepsy - antiepileptics, - vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

ucb pharma s.a. - lacosamide - epilepsies, partial - antiepileptics, - lacosamide ucb is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.,

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

ucb pharma sa - levetiracetam - epilepsy - antiepileptics, - keppra is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.keppra is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

ucb pharma sa - brivaracetam - epilepsy - antiepileptics, - briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.

Kanada - Ingliż - Health Canada

merck canada inc - norfloxacin - tablet - 400mg - norfloxacin 400mg - quinolones

Stati Uniti - Ingliż - NLM (National Library of Medicine)

lucid pharma llc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv) - sulfamethoxazole 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, usp and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris. it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

glenmark generics inc. usa - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets usp and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections: for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. acute ot

Stati Uniti - Ingliż - NLM (National Library of Medicine)

kaiser foundation hospitals - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, usp and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris. it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. for the treatment of acute otitis m

Malasja - Ingliż - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline consumer healthcare sdn. bhd. - paracetamol -